Search

Displaying results 821 - 830 of 1237 in total
  1. Drug

    Calcium levulinate

    go.drugbank.com/drugs/DB13800
    Approved

    This formulation is considered a low molecular weight organic calcium ion type that is easily absorbed through the intestinal wall [L2765].

  2. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid [A249070] that is produced in humans at a low concentration.

  3. Drug

    Iobitridol

    go.drugbank.com/drugs/DB12407
    ApprovedWithdrawn

    Iobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.

    Categories: Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media
  4. Drug

    MK-0773

    go.drugbank.com/drugs/DB16244
    Investigational

    MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).

  5. Drug

    Rivanicline

    go.drugbank.com/drugs/DB05855
    Experimental

    Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype. It was originally developed as a potential treatment for Alzheimer's disease for...

  6. Drug

    Eritoran

    go.drugbank.com/drugs/DB04933
    Investigational

    Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

  7. Drug

    Boron

    go.drugbank.com/drugs/DB11203
    ApprovedInvestigational

    It is a low-abundant metalloid that is a poor electrical conductor at room temperature.

  8. Drug

    Deflazacort

    go.drugbank.com/drugs/DB11921
    Approved

    [A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7.

  9. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risan...

  10. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.